The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIq-ai Ltd Regulatory News (IQAI)

Share Price Information for Iq-ai Ltd (IQAI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.40
Bid: 1.30
Ask: 1.50
Change: 0.00 (0.00%)
Spread: 0.20 (15.385%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.40
IQAI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Installation at Barrow Neurological Institute

11 Dec 2018 07:00

RNS Number : 9988J
IQ-AI Limited
11 December 2018
 

IQ-AI Ltd

("IQ-AI" or the "Company")

Imaging Biometrics® installation at Barrow Neurological Institute

Imaging Biometrics®, LLC ("IB"), a subsidiary of IQ-AI Limited (LON:IQAI), announced today that Barrow Neurological Institute: Dignity Health, St. Joseph's Hospital and Medical Center ("BNI") has installed a new IB Rad Tech software platform to help assess treatment response for patients with brain tumors. BNI has led the way in the development of cutting-edge diagnosis, treatment, and neurosurgical procedures for patients with brain tumors. Every year, Barrow treats thousands of patients with brain tumors, including some of the most difficult cases in the world. IB Rad Tech was chosen for its ability to efficiently generate quantitative maps of enhancing regions of tumor (Delta T1) and fractional tumor burden ("FTB"). IB's perfusion-derived FTB maps have been shown to aid clinicians in distinguishing tumor from non-tumor tissue.

IB Rad Tech offers customised workflows that automate the generation of sophisticated maps, outputs quality assurance indices, and can allow manual acknowledgement and intervention during intermediate processing steps. For example, one workflow used in generating quantitative Delta T1 and FTB maps relies on an exclusive machine-learned calibration technology termed "standardisation", which works for all platforms and field strengths. This step has proven superior to conventional normalisation techniques as it eliminates the need for the manual placement of regions of interest (ROIs) by radiology staff or physicians thereby reducing error and improving workflow efficiencies.

David Smith, CEO of IB, said, "Using this automated normalisation algorithm within an IB Rad Tech workflow enables objective longitudinal assessment and can help assess whether a certain treatment protocol is working for brain tumor patients. Removing the variability of the manually-placed ROI is a more repeatable and faster method to do inter- and intra-study comparisons for multi-center clinical trials as well."

"Without IB Rad Tech, we would not be able to process the high volume of studies we see at our site," said Dr. John Karis, MD, Director of MRI and brain imaging for the Department of Neuroradiology at Barrow Neurological Institute, Dignity Health St. Joseph's Hospital and Medical Center. "Our MR Technologists are now able to quickly and consistently generate IB's advanced maps, and the clinicians trust the science on which Delta T1 and FTBs are based", added Josef Debbins, PhD, Staff Scientist, Keller Center for Imaging Innovation at Barrow.

The Directors of the Company accept responsibility for the contents of this announcement.

For further information, please contact:

IQ-AI Limited

Trevor Brown/Vinod Kaushal/Qu Li

Tel: 020 7469 0930

Peterhouse Capital Limited (Financial Adviser and Broker)

Lucy Williams/Fungai Ndoro

Tel: 020 7220 9797

 

Barrow Neurological Institute / Dignity Health St. Joseph's Hospital and Medical Center has led the way in the development of cutting-edge diagnosis, treatment, and neurosurgical procedures for patients with brain tumors. Every year, Barrow treats thousands of patients with brain tumors, including some of the most difficult cases in the world. Since 1962, Barrow has grown into one of the premiere destinations in the world for neurology and neurosurgery. Experienced, highly skilled, and comprehensive teams of neurological specialists provide a complete spectrum of care-from diagnosis through outpatient neurorehabilitation-under one roof. Barrow Neurological Institute: Discover. Educate. Heal.

Imaging Biometrics, a subsidiary of IQ-AI Limited (LON:IQAI), develops and provides -visualisation and analytical solutions that enable clinicians to better diagnose and treat diseases with greater confidence. Through close collaboration with top researchers and clinicians, sophisticated advancements are translated into platform-independent software plug-ins which can extend the base functionality of workstations, imaging systems, PACS, or medical viewers. By design, IB's advanced visualisation software seamlessly integrates into routine workflows. For more information about Imaging Biometrics, visit the company's website at www.imagingbiometrics.com.

IQ-AI Limited (Ticker:IQAI) is the parent company of StoneChecker® and Imaging Biometrics® focused on advanced and state of the art medical software and services. (www.iq-ai.ltd).

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
STRGGGUAPUPRGWU
Date   Source Headline
16th Jul 20187:00 amRNSPlacing, Notice of AGM and GM
2nd Jul 20188:34 amRNSMedimsight and IB Enter into Partnership
13th Jun 20187:00 amRNSImaging Biometrics and QMENTA announce partnership
9th May 20187:00 amRNSIB Software Chosen by St. Savvas Oncology Hospital
30th Apr 20184:25 pmRNSFinal Results
11th Apr 20187:00 amRNSIMAGING BIOMETRICS ANNOUNCES PARTNERSHIP
29th Mar 20182:52 pmRNSTotal Voting Rights
13th Mar 201810:54 amRNSTotal Voting Rights
13th Mar 20187:40 amRNSAcquisition of Imaging Biometrics
6th Mar 20187:00 amRNSStoneChecker signs agreement with Korea ISG
8th Feb 20181:44 pmRNSPotential Acquisition
8th Feb 20189:05 amRNSSecond Price Monitoring Extn
8th Feb 20189:00 amRNSPrice Monitoring Extension
11th Dec 20177:00 amRNSCE marked release of StoneChecker® Software
6th Nov 20174:40 pmRNSSecond Price Monitoring Extn
6th Nov 20174:35 pmRNSPrice Monitoring Extension
26th Oct 20177:00 amRNSUpdate on Business Operations
9th Oct 20172:33 pmRNSHolding(s) in Company
18th Sep 20177:00 amRNSUpdate on Product Development and Warrant Exercise
4th Sep 20179:49 amRNSStone Checker Update
30th Aug 201710:04 amRNSHolding(s) in Company
17th Aug 20177:01 amRNSDirector Dealings
17th Aug 20177:00 amRNSHalf-year Report
14th Aug 201710:12 amRNSHolding(s) in Company
27th Jul 20174:40 pmRNSSecond Price Monitoring Extn
27th Jul 20174:35 pmRNSPrice Monitoring Extension
11th Jul 20177:00 amRNSUpdate on Operations
3rd Jul 20177:00 amRNSConversion of Convertible Loan Notes into Equity
27th Jun 20174:40 pmRNSSecond Price Monitoring Extn
27th Jun 20174:35 pmRNSPrice Monitoring Extension
16th Jun 20177:00 amRNSReadmission to the London Stock Exchange
15th Jun 20171:42 pmRNSResult of Annual General Meeting & General Meeting
19th May 20177:00 amRNSProspectus, Placing & Expected Readmission
28th Apr 20173:12 pmRNSFinal Results
27th Feb 201711:51 amRNSHolding(s) in Company
20th Jan 20171:30 pmRNSAppointment of Non-Executive Director
26th Aug 201612:06 pmRNSHalf-year Report
30th Jun 201612:58 pmRNSProposed Acquisition and Suspension of Listing
31st May 20161:33 pmRNSHolding(s) in Company
27th May 201611:39 amRNSResult of AGM
5th May 20164:15 pmRNSHolding(s) in Company
4th May 20167:00 amRNSNotice of AGM
20th Apr 20167:00 amRNSHolding(s) in Company
20th Apr 20167:00 amRNSFinal Results
5th Apr 201610:48 amRNSStatement re Update
20th Nov 20157:00 amRNSBoard changes, corporate update, issue of CLN
21st Oct 20157:00 amRNSAppointment of Financial Adviser and Broker
25th Aug 20153:29 pmRNSHalf Yearly Report
16th Jul 201511:17 amRNSHolding(s) in Company
16th Jul 201511:15 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.